Chugai investing S$476m more into S'pore facility
Funds will be used to boost Japanese drug maker's local employee base and antibody R&D pipeline
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
JAPANESE drug maker Chugai Pharmaceutical on Wednesday announced that it will invest S$476 million from now until 2021 into its research institute in Singapore, Chugai Pharmabody Research (CPR).
When CPR first set up its corporate laboratory here in 2012 to develop antibody drugs, it planned to pour about S$200 million into antibody research over the subsequent five years.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
